Search Results - "Lalani, AS"

Abstract P1-17-07: Preclinical characterization of neratinib in a blood-brain barrier co-culture model: Therapeutic implications for breast cancers with brain metastases by Martin, TA, Lalani, AS, Avogadri Connors, F, Bryce, RP, Jiang, WG

“…Background: Breast cancer patients who develop brain metastases have poor prognosis/short overall survival. Human epidermal growth factor receptor 2 (HER2)…”
Get full text

Abstract P2-03-05: Identification, clinical characteristics and treatment outcomes of somatic human epidermal growth factor receptor 2 (ERBB2) mutations in metastatic breast cancer patients by Jongen, L, Floris, G, Lambrechts, D, Laenen, A, Neven, P, Cutler, RE, Lalani, AS, Wildiers, H

“…Background Metastatic breast cancer (MBC) is seen as incurable and advances in new therapies or targets are necessary. Targeted therapies against human…”
Get full text

Abstract P3-07-07: The pan-HER inhibitor, neratinib and wingless-type MMTVs (Wnt)/Wnt regulators in human breast cancer; a biological and clinical perspective by Owen, S, Ruge, F, Lalani, AS, Avogadri-Connors, F, Bryce, RP, Davies, E, Jiang, WG

“…Background. Neratinib is an orally available tyrosine kinase inhibitor that irreversibly binds and inhibits EGFR, HER2 and HER4 receptor tyrosine kinases…”
Get full text

Abstract P3-04-03: Identification, clinical characteristics and treatment outcomes of somatic human epidermal growth factor receptor 2 ( ERBB2 ) mutations in metastatic breast cancer patients by Jongen, L, Floris, G, Lambrechts, D, Laenen, A, Neven, P, Mann, G, Cutler, RE, Lalani, AS, Wildiers, H

“…Background The human epidermal growth factor receptor 2 (ERBB2) can be altered by somatic mutations (with/without ERRB2 amplification) that likely drive…”
Get full text

Abstract P4-05-03: Heat shock protein 27 (HSP27) and HER2 positively correlate in breast cancer and effect cell responsiveness to neratinib and cMET inhibitor by Owen, S, Sanders, AJ, Ruge, F, Lalani, AS, Avogadri-Connors, F, Bryce, RP, Jiang, WG

“…Background: Upregulation of heat shock protein-27 (HSP27), a key member of the HSP family, has been shown to confer resistance to chemotherapy and radiotherapy…”
Get full text

Abstract P6-03-02: Budesonide and colesevelam reduce neratinib-induced diarrhea in a rat model by Bowen, JM, Secombe, KR, Ball, IA, Shirren, J, Wignall, AD, Finnie, JW, Olek, E, Martin, D, Lalani, AS, Keefe, D

“…Background: Neratinib (Puma Biotechnology Inc.) is an irreversible pan-HER tyrosine kinase inhibitor approved for use as extended adjuvant therapy in women…”
Get full text

Abstract P6-17-12: Neratinib in combination with trastuzumab is superior to each alone and to pertuzumab plus trastuzumab in HER2-positive in vivo breast cancer models by Veeraraghavan, J, Sethunath, V, Qin, L, Shea, MJ, Mitchell, T, De Angelis, C, Nanda, S, Diala, I, Lalani, AS, Hilsenbeck, SG, Rimawi, MF, Osborne, CK, Schiff, R

“…Background: Lapatinib (L) plus trastuzumab (T) alone or with endocrine therapy for HER2+/ER+ tumors but without chemotherapy, yielded complete tumor…”
Get full text

Abstract PD2-05: Inhibition of mutant HER2 results in synthetic lethality when combined with ER antagonists in ER+/HER2 mutant human breast cancer cells by Croessmann, S, Zabransky, DJ, Cutler, RE, Lalani, AS, Park, BH, Arteaga, CL

“…Background: Human epidermal growth factor receptor 2 (ERBB2 or commonly known as HER2) missense mutations have been reported in 2-4% of breast cancers and…”
Get full text

Abstract PD3-05: Co-occurring gain-of-function mutations in HER2 and HER3 cooperate to enhance HER2/HER3 binding, HER-dependent signaling, and breast cancer growth by Hanker, AB, Koch, JP, Ye, D, Sliwoski, G, Sheehan, J, Kinch, LN, Red Brewer, M, He, J, Miller, VA, Lalani, AS, Cutler, RE, Croessmann, S, Zabransky, DJ, Meiler, J, Arteaga, CL

“…ERBB2, the gene encoding HER2, is mutated in 2-4% of breast cancers. The HER2 tyrosine kinase inhibitor neratinib has shown clinical activity against breast…”
Get full text

Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor by JIANMIN LIN, LALANI, Alshad S, MITALO, Kari, JOOSS, Karin, HARDING, Thomas C, GONZALEZ, Melissa, WU, Wei-Wei, BO LUAN, GUANG HUAN TU, KOPRIVNIKAR, Kathryn, VANROEY, Melinda J, YULONG HE

“…The presence of metastases in regional lymph nodes is a strong indicator of poor patient survival in many types of cancer. It has recently been shown that the…”
Get full text

Abstract P3-03-03: An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer by Hanker, AB, Red Brewer, M, Sheehan, JH, Koch, JP, Lanman, R, Hyman, DM, Cutler, RE, Lalani, AS, Cross, D, Lovly, CM, Meiler, J, Arteaga, CL

“…ERBB2, the gene encoding HER2, is mutated in 2-4% of breast cancers. The HER2 irreversible tyrosine kinase inhibitor (TKI) neratinib has shown clinical…”
Get full text

Abstract PD3-12: PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial by Chia, SKL, Martin, M, Holmes, FA, Ejlertsen, B, Delaloge, S, Moy, B, Iwata, H, von Minckwitz, G, Mansi, J, Barrios, CH, Gnant, M, Tomašević, Z, Denduluri, N, Šeparović, R, Kim, S-B, Hugger Jakobsen, E, Harvey, V, Robert, N, Smith, J, Harker, G, Lalani, AS, Zhang, B, Eli, LD, Buyse, M, Chan, A

“…Background: Neratinib is a pan-HER tyrosine kinase inhibitor that blocks the PI3K/Akt and MAPK signaling pathways downstream from HER2. The international,…”
Get full text

Abstract P1-13-03: Effects of neratinib after trastuzumab-based adjuvant therapy in hormone receptor-positive HER2+ early-stage breast cancer: Exploratory analyses from the phase III ExteNET trial by Chia, SKL, Martin, M, Iwata, H, Moy, B, Lalani, AS, Holmes, FA, Mansi, J, von Minckwitz, G, Buyse, M, Delaloge, S, Ejlertsen, B, Yao, B, Murias Rosales, A, Hellerstedt, B, Cold, S, Inoue, K, Shen, Z-Z, Galeano, T, Barrios, CH, Chan, A

“…Background: The international, randomized, placebo-controlled phase III ExteNET trial showed that a 1-year course of neratinib after trastuzumab-based adjuvant…”
Get full text

Abstract P1-13-08: Extended adjuvant neratinib/fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2+ tumors following treatment with chemotherapy and anti-HER2 therapy by Sudhan, DR, Schwarz, LJ, Guerrero-Zotano, AL, Nixon, M, Formisano, L, Croessmann, S, Gonzalez Ericsson, PI, Sanders, ME, Balko, JM, Avogadri-Connors, F, Cutler, RE, Lalani, AS, Bryce, R, Auerbach, A, Arteaga, CL

“…Background: Neratinib is a potent, irreversible pan-HER tyrosine kinase inhibitor. The phase III trial ExteNET showed improved disease-free survival in…”
Get full text

Abstract PD3-06: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT trial by Smyth, LM, Piha-Paul, SA, Saura, C, Loi, S, Lu, J, Shapiro, GI, Juric, D, Mayer, IA, Arteaga, C, de la Fuente, M, Brufksy, AM, Mau-Sørensen, M, Arnedos, M, Moreno, V, Sohn, J-H, Schwartzberg, L, Gonzàlez-Farré, X, Cervantes, A, Mann, G, Shahin, S, Cutler, RE, Eli, LD, Xu, F, Bagulho, T, Lalani, AS, Bryce, R, Solit, DB, Hyman, DM, Meric-Bernstam, F, Baselga, J

“…Background: HER2 mutations define a rare subset of metastatic breast cancer (MBC) with a unique mechanism of oncogenic addiction to HER2 signaling. Neratinib,…”
Get full text

Neratinib induces estrogen receptor function and sensitizes HER2-mutant breast cancer to anti-endocrine therapy by Scaltriti, M, Carmona, F.J, Toska, E, Cocco, E, Hyman, D, Cutler, R, Avogadri-Connors, F, Wick, M.J, Papadopoulos, K.P, Lalani, A.S, Baselga, J

“…Background: Recent large scale next-generation sequencing studies have revealed recurrent activating mutations of ERBB2 (the gene encoding HER2) across a wide…”
Get full text

Abstract PD5-05: Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial by Hyman, DM, Piha-Paul, SA, Rodón, J, Saura, C, Puzanov, I, Shapiro, GI, Loi, S, Joensuu, H, Hanrahan, AJ, Modi, S, Lalani, AS, Xu, F, Garza, SJ, Cutler, RE, Bryce, R, Meric-Bernstam, F, Baselga, J, Solit, DB

“…Background: Somatic ERBB2 (HER2) mutations occur in approximately 2% of patients with breast cancer and are found in a predominantly mutually exclusive manner…”
Get full text

Use of Chemokine Receptors by Poxviruses by Lalani, Alshad S., Masters, Jennefer, Zeng, Wei, Barrett, John, Pannu, Rajeet, Everett, Helen, Arendt, Christopher W., McFadden, Grant

“…Chemokine receptors serve as portals of entry for certain intracellular pathogens, most notably human immunodeficiency virus (HIV). Myxoma virus is a member of…”
Get full text

The purified myxoma virus gamma interferon receptor homolog M-T7 interacts with the heparin-binding domains of chemokines by Lalani, A S, Graham, K, Mossman, K, Rajarathnam, K, Clark-Lewis, I, Kelvin, D, McFadden, G

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Evasion and exploitation of chemokines by viruses by Lalani, Alshad S., McFadden, Grant

“…Chemokines and chemokine receptors play a critical role in the host defense against viruses by mobilizing leukocytes to sites of infection, injury and…”
Get full text